Advanced search
Publication Cover
Acta Oncologica Volume 49, 2010 - Issue 1
Journal homepage
992
Views
8
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study

Annika Malmström Unit of Advanced Palliative Home Care, Linköping University Hospital, SwedenCorrespondence[email protected]
,
Jörgen Hansen Department of Oncology, Central Hospital, Karlstad, Sweden
,
Lena Malmberg Department of Oncology, Ryhov Hospital, Jönköping, Sweden
,
Lena Carlsson Department of Oncology, County Hospital, Sundsvall, Sweden
,
Jan-Henry Svensson Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden
,
Johan Ahlgren Department of Oncology, County Hospital, Gävle, Sweden
,
Cecila Ahlin Department of Oncology, Örebro University Hospital, Sweden
,
Tomas Jansson Department of Oncology, Trondheim University Hospital, Norway
&
Ronny Westberg RW Clinical Research, Stockholm, Sweden
 show all
Pages 35-41 | Received 02 Mar 2009, Accepted 18 Aug 2009, Published online: 20 Oct 2009

References

  • Silvestris N, Cinieri S, La Torre I, . Role of gemcitabine in metastatic breast cancer patients: A short review. Breast 2008; 17:220–6.
  • Ershler W. Capecitabine monotherapy: Safe and effective treatment for metastatic breast cancer. Oncologist 2006; 11:325–35.
  • Sawada N, Fujimoto-Ouchi K, Ishikawa T, . Antitumor activity of combination therapy with capecitabine plus vinorelbin, and capecitabine plus gemcitabine in human tumor xenograft models. Proc Am Assoc Cancer Res 2002; 43:5388.(Abstract)
  • Andres R, Mayordomo JI, Lara R, . Gemcitabine/capecitabine in patients with metastatic breast cancer pre-treated with anthracyclines and taxanes. Clin Breast Cancer 2005; 6:158–62.
  • Benekli M, Yildis R, Uner A, . Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Oncology 2007; 72:308–13.
  • Giannessi P, Martell F, Di Marsico R, . Gemcitabine in combination with capecitabine in metastatic breast carcinoma: A phase I–II study. J Clin Oncol 2005; 23Suppl:870.(Abstract)
  • Sikov WM, Theall KP, Seidler R, . Gemcitabine and capecitabine in metastatic breast cancer (MBC): Brown University Oncology group (BrUOG) phase II study. J Clin Oncol 2005; 23Suppl:785.(Abstract)
  • Ahn J, Kim S, Lee Y, . Phase II study of gemcitabine and capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. J Clin Oncol 2005; 23Suppl:895.(Abstract)
  • Teletaeva G, Erndiev S, Moiseyenko V. Phase II trial of Gemcitabine and Capecitabine combination in patients with metastatic breast cancer resistant to standard therapy. Ann Oncol 2003; 14Suppl 3:66.(Abstract)
  • Pérez-Manga G, López-Criado P, Mendez M, . Gemcitabine (G) plus capecitabine (C) in previously treated metastatic breast cancer (MBC) patients. Final results from a phase II GOTI trial GOTI trial. Breast Cancer Res Treat 2004; 88Suppl 1:5063.(Abstract)
  • Wirk B, Perez E. Role of gemcitabine in breast cancer management: An update. Semin Oncol 2006; 33:S6–S14.
  • Seidman A, O´Shaughnessy J, Misset JL. Single-agent capecitabine: A reference treatment for taxane-pretreated metastatic breast cancer? Oncologist 2002; 7Suppl 6:20–8.
  • Albain K, Nag S, Calderillo-Ruiz G, . gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008; 263:950–7.
  • O´Shaughnessy J, Miles D, Vukelja S, . Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002; 20:2812–23.
  • Chan S. Gemcitabine plus Docetaxel versus capecitabine plus docetaxel for patients with anthracycline-pretreated metastatic breast cancer: A review of results of a European Phase III trial. EJC 2005;(Suppl 3):17–21.
  • Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143–51.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.